相关实验视频
Updated: Jun 5, 2025

08:51
Quantification of Coenzyme A in Cells and Tissues
Published on: September 27, 2019
8.3K
泛丁酸酶相关的神经退行症的病理学和治疗方法
Robert Kwinta1, Katarzyna Kopcik2, Agnieszka Koberling3
1Municipal Hospital in Zabrze, Poland.
Postepy psychiatrii neurologii
|December 16, 2024
概括
潘托酸酶相关的神经退行症 (PKAN) 是一种遗传性脑部疾病. 目前的治疗方法可以控制症状,但未来需要针对遗传和环境因素的个性化疗法.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 生物化学 生化学
背景情况:
- 潘托酸酶相关的神经退行症 (PKAN) 是一种罕见的神经退行性疾病.
- 它源于PANK2基因突变,导致大脑铁积累并影响协酶A通路.
研究的目的:
- 审查有关PKAN病理生理学,诊断和治疗的当前科学文献.
- 专注于2017年至2024年间发表的研究.
主要方法:
- 审查最近的科学报告.
- 诊断成像 (MRI) 和遗传检测的分析.
- 检查当前和新兴的治疗策略.
主要成果:
- PKAN存在两种临床类型,发病和进展各异.
- 诊断通常涉及特征性的MRI发现,如"虎眼"标志.
- 目前的治疗方法主要是症状性,包括药物治疗和深度大脑刺激.
结论:
- 对于PKAN存在有限的有效治疗方法,需要症状管理.
- 未来的PKAN治疗方法可能会个性化,考虑遗传和环境因素.
- 进一步的研究对于开发有针对性的疗法至关重要.
相关概念视频
Parkinson's Disease: Overview
476
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
476
Parkinson's Disease: Treatment
216
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
216
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Alzheimer's Disease: Treatment
162
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162
Protein Kinases and Phosphatases
13.0K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.0K

